Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2006 1
2007 3
2008 1
2009 3
2010 4
2011 9
2012 6
2013 13
2014 8
2015 16
2016 1
2017 2
2018 1
2019 3
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27354620

65 results

Results by year

Filters applied: . Clear all
Page 1
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Röhm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, Walter C, Neubauer H, Wallwiener D, Fehm T. Hartkopf AD, et al. Breast Cancer Res Treat. 2013 Apr;138(2):509-17. doi: 10.1007/s10549-013-2470-9. Epub 2013 Mar 15. Breast Cancer Res Treat. 2013. PMID: 23494674
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ. Bethune GC, et al. Histopathology. 2015 Dec;67(6):880-7. doi: 10.1111/his.12723. Epub 2015 Jun 9. Histopathology. 2015. PMID: 25913507
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15. Cancer Chemother Pharmacol. 2013. PMID: 23673443
65 results